Catalyst Pharma (CPRX) Received its Third Buy in a Row


After Piper Jaffray and Oppenheimer gave Catalyst Pharma (NASDAQ: CPRX) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein maintained a Buy rating on Catalyst Pharma today and set a price target of $9. The company’s shares closed yesterday at $3.16.

Fein commented:

“Our price target of $9/share is based on an equally weighted composite of: (a) $10.55/ share, as a 35x multiple of taxed and diluted 2024 GAAP EPS of $0.90 discounted back to 2018 at 20%; and (b) an NPV of discounted cash flows between 2019-2024 of $7.48/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include failure of Firdapse to achieve peak commercial revenue estimates in our model due to market size, penetration rates, and/or pricing.”

According to TipRanks.com, Fein is a 3-star analyst with an average return of 2.1% and a 40.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Catalyst Pharma with a $8.20 average price target, implying a 159.5% upside from current levels. In a report issued on May 6, Piper Jaffray also maintained a Buy rating on the stock with a $7.50 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.16 and a one-year low of $1.85. Currently, Catalyst Pharma has an average volume of 2.64M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular at

Read More on CPRX:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts